Home > Gastroenterology > UEGW 2021 > Updates in Biologics > Risankizumab meets primary endpoints in maintenance study for CD patients

Risankizumab meets primary endpoints in maintenance study for CD patients

Presented by
Prof. Marc Ferrante, University Hospital Leuven, Belgium
Conference
UEGW 2021
Trial
Phase 3, FORTIFY
Clinical remission was sustained throughout the 52-week FORTIFY maintenance study for patients with Crohn’s disease (CD) who responded well to risankizumab induction therapy. Moreover, endoscopic remission and deep remission endpoints revealed a consistent dose-response relationship of continued risankizumab use. Risankizumab showed a favourable safety profile and was generally well tolerated.

Risankizumab is a humanised monoclonal antibody inhibiting IL-23 that has demonstrated greater efficacy than placebo in two 12-week phase 3 induction studies (ADVANCE [NCT03105128] and MOTIVATE [NCT03104413]). Patients with moderate-to-severe CD who responded well to risankizumab (600 mg or 1,200 mg intravenous injection every 4 weeks) were eligible for the FORTIFY maintenance study (NCT03105102) [1]. Participants were randomised 1:1:1 to 180 mg risankizumab (subcutaneous injection every 2 months; n=179), 360 mg risankizumab (n=184), or placebo (n=179). Approximately 70% of the participants had an inadequate response to at least 1 prior biologic therapy. Co-primary endpoints were clinical remission and endoscopic response. Prof. Marc Ferrante (University Hospital Leuven, Belgium) presented the findings of the trial.

Crohn’s Disease Activity Index (CDAI) clinical remission scores showed that patients who continued risankizumab were significantly more likely to achieve clinical remission at week 52 than patients who switched to placebo in the maintenance study (risankizumab 180 mg, 55.4%; P=0.003; risankizumab 360 mg, 52.2%; P=0.005; placebo, 40.9%). However, a large proportion of placebo users achieved clinical remission as well. Prof. Ferrante argued that a carry-over effect of the risankizumab induction therapy is a possible explanation for this result. The endoscopic response, defined as a reduction of >50% in the simple endoscopic score (SES)-CD from induction baseline, showed clear benefits of risankizumab over placebo (risankizumab 180 mg, 47.1%; P<0.001; risankizumab 360 mg, 46.5%; P<0.001; placebo, 22.0%).

Adverse events (AEs) were evenly distributed across the 3 study groups. Likewise, there was no apparent difference between the number of serious AEs between the study conditions (risankizumab 180 mg, 33; risankizumab 360 mg, 35; placebo, 31). Risankizumab receivers did not show an increased risk of serious infections.

  1. Ferrante M, et al. Efficacy and safety of risankizumab as maintenance therapy in patients with Crohn’s disease: 52 week results from the phase 3 FORTIFY study. LB13, UEG Week 2021 Virtual Congress, 03–05 October.

 

Copyright ©2021 Medicom Medical Publishers



Posted on